Search results

Filters
Close
ADDED DATE
Added date
AUTHOR Please select
TOPICS Please select
WATCH / LISTEN / READ TIME
AHA 2019: Colchicine in Percutaneous Coronary Intervention (PCI)
Author(s): Binita Shah Added: 4 years ago
Dr Binita Shah (NYU Langone Health, New York, NY, US) discusses Colchicine in Percutaneous Coronary Intervention (PCI). Questions: 1.What is colchicine and why study it in PCI? 2.What was the study design, patient population and primary and secondary outcomes? 3.What were your outcomes? 4.How do these compare to those in the COLCOT study? 5.How should your study be interpreted in clinical… View more

Intervention
Dr Duncan Hogg, gained his medical qualification at the University of Aberdeen in 1994. In 1997 he became a Member of the Royal College of Physicians. Dr Hogg received his general cardiology training at Aberdeen Royal Infirmary and completed specialist training in Cardiology & General Internal Medicine (GIM) in 2007. Dr Hogg has Specialist Registration with the General Medical Council for… View more
SYNTAX II Trial: 5yr Data Shows Reduction in MACE in PCI
Author(s): Adrian P Banning Added: 2 years ago
In this interview, Professor Adrian Banning (John Radcliffe Hospital, Oxford, UK) discusses the five-year outcomes of the SYNTAX II trial. This study aims to evaluate the impact of new technologies in percutaneous coronary intervention (PCI) by comparing the outcomes of these procedures to the original SYNTAX trial. The study showed that PCI moved forward considerably in the last 5 years, it is… View more

Intervention
Ventricular Assist Device - ABIOMED, Inc.
Abiomed: Manufacturer of Impella®Percutaneous Ventricular Assist Device Abiomed, founded in 1981, is a global pioneer in healthcare technology, with a mission to recover hearts and save lives. From the World’s first total replacement heart pump to the World’s smallest heart pump, Abiomed has developed a family of ventricular assist devices (VAD), namely the Impella® platform of percutaneous… View more
CardioNerds @AHA23: ORBITA-2: PCI for Stable Angina
Author(s): Rasha Al-Lamee , Christopher Rajkumar , Nazli Okumus Added: 5 months ago
AHA 2023 — Investigators of ORBITA-2 trial, Dr Rasha Al-Lamee and Dr Christopher Rajkumar (Imperial College London, UK) talked with CardioNerds Ambassador, Dr Nazli Okumus about the randomised, placebo-controlled trial (NCT03742050) that compared the effects of coronary angioplasty versus placebo procedure on symptoms of stable angina without background anti-anginal therapy at 12 weeks.The ORBITA… View more

Intervention
Research Area(s) / Expertise: Job title: Interventional Cardiologist
DrColm Hanratty is anInterventional Cardiologist atMater Private Hospital, Dublin, IE. Prior to joining Mater Private Hospital,he was clinical lead within the Belfast Trust for 8 years. He has sub-specialty interest in the management of complex Percutaneous Coronary Intervention (PCI) and is internationally recognised as one of the leading interventionists in terms of complex and chronic total… View more
ACC.24: FFR or Culprit-Only PCI in STEMI
Author(s): Felix Böhm Added: 1 week ago
ACC.24 — Investigator, Dr Felix Böhm (Danderyd Hospital, SE) joins us to discuss the findings from a study investigating fractional flow reserve-guided complete or culprit-only percutaneous coronary intervention (PCI) in patients with ST-elevation myocardial infarction (MI).1542 patients were enrolled in the trial, who were randomized 1:1 to receive either FFR-guided PCI of non-culprit lesions… View more

MI/ACS

Intervention
JIMPosters
Author(s): Jumpei Koike , Yoshihiro Iwasaki , Toshinori Ko , et al Added: 2 years ago

Intervention
PCI for Ischemic Left Ventricular Dysfunction in 2023
Author(s): Angela Hoye , Rodney H Stables , Anthony Mathur , et al Added: 1 year ago
BCIS ACI 2023­ – Dr Angela Hoye (Hull & East Yorkshire Hospitals, UK), is joined by Dr Rod Stables (Liverpool Heart and Chest Hospital, UK), Dr Anthony Mathur (Barts Health NHS Trust, UK) and Dr Sen Devadathan (Royal Cornwall Hospitals NHS Trust, UK) to have a critical discussion on the BCIS-REVIVED trial and what it means for patients with ischemic left ventricular dysfunction in 2023. Data… View more

Heart Failure

Intervention